*Fraunhofer IME, Department of Pharmaceutical Product Development
†Institute for Molecular Biotechnology, RWTH-Aachen
§Department of Experimental Medicine and Immunotherapy, Helmholtz-Institute for Applied Medical Engineering, AACHEN
‡Zentralinstitut für Laboratoriumsmedizin und Pathobiochemie, Charite, Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany
Financial Disclosure: All authors have declared there are no financial conflicts of interest in regard to this work. This work was partially funded by grants 106521 from the German cancer foundation, and IMHOTEP of the Fraunhofer-Gesellschaft, both to Stefan Barth.
Reprints: Christian Hetzel, Fraunhofer IME, Department of Pharmaceutical Product Development, Forckenbeckstr. 6, 52074 AACHEN, Germany (e-mail: [email protected]).
Received for publication November 19, 2007; accepted January 20, 2008
Stefan Barth and Michael Stöcker equally contributed to principle investigatorship.